Determination of Regulatory Review Period for Purposes of Patent Extension; EXEM FOAM

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of EXEM FOAM, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).